Bigfoot Biomedical Stock

bigfootbiomedical.comHealthcare / Other HealthcareFounded: 2014Funding to Date: $92.5MM

Bigfoot Biomedical is a medical device company developing technologies to significantly reduce the cognitive, emotional, and financial burden of insulin-requiring diabetes. Founded in 2014 by a team of people with personal connections to type 1 and type 2 diabetes with the vision to create a world where technology frees people from the burdens of living with insulin-requiring diabetes, Bigfoot Biomedical is headquartered in Milpitas, California.

Register To Buy and Sell Shares

For more details on financing and valuation for Bigfoot Biomedical, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Bigfoot Biomedical’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Bigfoot Biomedical.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Bigfoot Biomedical investors also invested in these private companies


Management Team

Bryan Mazlish
Co-Founder & President
Brett Hale
Chief Financial Officer
Ian Hanson
Chief Technology Officer
Jeffrey Brewer
Co-Founder & Chief Executive Officer
James Malone
Chief Medical Officer
Matt Rainville
Chief Commercial Officer

Board Members

Thomas Brener
Quadrant Capital Advisors

Bigfoot Biomedical’s stock FAQs


Can you buy Bigfoot Biomedical’s stock?

Bigfoot Biomedical is not publicly traded on NYSE or NASDAQ in the U.S. To buy Bigfoot Biomedical’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Bigfoot Biomedical’s stock?

Yes, you can sell stock of a private company like Bigfoot Biomedical. Forge can help you sell your Bigfoot Biomedical stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is Bigfoot Biomedical’s stock price?

Bigfoot Biomedical is a privately held company and therefore does not have a public stock price. However, you may access Bigfoot Biomedical’s private market stock price with Forge Data.

What is Bigfoot Biomedical’s stock ticker symbol?

Bigfoot Biomedical does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Bigfoot Unity™ Program Now Available in US, Revolutionizes How Clinicians Support Patients to Successfully Manage their Diabetes

Press Release Bigfoot Biomedical announced today that its innovative Bigfoot Unity™ Diabetes Management Program is now available to diabetes clinics and endocrinology practices in select markets across the U.S. The groundbreaking program reimagines how clinicians...

Bigfoot Biomedical® Receives FDA Clearance for Bigfoot Unity™ Diabetes Management System, Featuring First-of-its-Kind Smart Pen Caps for Insulin Pens used to Treat Type 1 and Type 2 Diabetes

Press Release Bigfoot Biomedical, a company dedicated to better health outcomes for people with insulin-requiring diabetes, announced today that the FDA has granted 510(k) clearance for first-of-its-kind Bigfoot Unity™ Diabetes Management System, which features connected...

Bigfoot Biomedical Secures Up To $57M in Debt and Equity Financing

Bigfoot Biomedical, a Milpitas, CA-based company dedicated to health outcomes for people with insulin-requiring diabetes, secured new debt and equity financing of up to $57m from Madryn Asset Management
Updated on: Jun 24, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.